Patents by Inventor Yi-Qing Zhou

Yi-Qing Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210288819
    Abstract: An identity certificate may be issued to a blockchain node. The issuance may include issuing a first identity certificate to a first terminal and receiving a second identity certificate issuance request that is from the first terminal. A second identity certificate may be issued to the first terminal, and a third identity certificate issuance request is received from the second terminal. A third identity certificate is issued to the second terminal, so that the second terminal forwards the third identity certificate to the third terminal.
    Type: Application
    Filed: June 2, 2021
    Publication date: September 16, 2021
    Applicant: Tencent Technology (Shenzhen) Company Limited
    Inventors: Mao Cai LI, Zong You WANG, Kai Ban ZHOU, Chang Qing YANG, Hu LAN, Li KONG, Jin Song ZHANG, Yi Fang SHI, Geng Liang ZHU, Qu Cheng LIU, Qiu Ping CHEN
  • Publication number: 20090111869
    Abstract: The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.
    Type: Application
    Filed: June 18, 2008
    Publication date: April 30, 2009
    Applicant: Kosan Biosciences, Inc.
    Inventors: Daniel SANTI, David C. Myles, Zong-Qiang Tian, C. Richard Hutchinson, Robert Johnson, Yi-Qing Zhou, Li Feng
  • Patent number: 7405208
    Abstract: The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: July 29, 2008
    Assignee: Kosan Biosciences, Inc.
    Inventors: Daniel Santi, David C. Myles, Zong-Qiang Tian, C. Richard Hutchinson, Robert Johnson, Yi-Qing Zhou, Li Feng
  • Publication number: 20050261263
    Abstract: The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.
    Type: Application
    Filed: February 11, 2005
    Publication date: November 24, 2005
    Inventors: Daniel Santi, David Myles, Zong-Qiang Tian, C. Hutchinson, Robert Johnson, Yi-Qing Zhou, Li Feng
  • Patent number: 6872715
    Abstract: The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: March 29, 2005
    Assignee: Kosan Biosciences, Inc.
    Inventors: Daniel Santi, David C. Myles, Zong-Qiang Tian, C. Richard Hutchinson, Robert Johnson, Yi-Qing Zhou, Li Feng
  • Publication number: 20030114450
    Abstract: The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.
    Type: Application
    Filed: August 5, 2002
    Publication date: June 19, 2003
    Inventors: Daniel Santi, David C. Myles, Zong-Qiang Tian, C. Richard Hutchinson, Robert Johnson, Yi-Qing Zhou, Li Feng